Abstract
Cancer immunotherapies have unique toxicities. Establishment of grading scales and standardized grade-based treatment algorithms for toxicity syndromes can improve the safety of these treatments, as observed for cytokine release syndrome (CRS) and immune effector cell associated neurotoxicity syndrome (ICANS) in patients with B cell malignancies treated with chimeric antigen receptor (CAR) T cell therapy. We have observed a toxicity syndrome, distinct from CRS and ICANS, in patients treated with cell therapies for tumors in the central nervous system (CNS), which we term tumor inflammation-associated neurotoxicity (TIAN). Encompassing the concept of ‘pseudoprogression,’ but broader than inflammation-induced edema alone, TIAN is relevant not only to cellular therapies, but also to other immunotherapies for CNS tumors. To facilitate the safe administration of cell therapies for patients with CNS tumors, we define TIAN, propose a toxicity grading scale for TIAN syndrome and discuss the potential management of this entity, with the goal of standardizing both reporting and management.
This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Waldman, A. D., Fritz, J. M. & Lenardo, M. J. A guide to cancer immunotherapy: from T cell basic science to clinical practice. Nat. Rev. Immunol. 20, 651–668 (2020).
Medikonda, R., Dunn, G., Rahman, M., Fecci, P. & Lim, M. A review of glioblastoma immunotherapy. J. Neurooncol. 151, 41–53 (2021).
Huang, B. et al. Current immunotherapies for glioblastoma multiforme. Front. Immunol. 11, 603911 (2020).
Desjardins, A. et al. Recurrent glioblastoma treated with recombinant poliovirus. N. Engl. J. Med. 379, 150–161 (2018).
Zhang, M., Choi, J. & Lim, M. Advances in immunotherapies for gliomas. Curr. Neurol. Neurosci. Rep. 22, 1–10 (2022).
Brown, C. E. et al. The future of cancer immunotherapy for brain tumors: a collaborative workshop. J. Transl. Med. 20, 236 (2022).
Lim, M., Xia, Y., Bettegowda, C. & Weller, M. Current state of immunotherapy for glioblastoma. Nat. Rev. Clin. Oncol. 15, 422–442 (2018).
Mount, C. W. et al. Potent antitumor efficacy of anti-GD2 CAR T cells in H3-K27M+ diffuse midline gliomas. Nat. Med. 24, 572–579 (2018).
Theruvath, J. et al. Locoregionally administered B7-H3-targeted CAR T cells for treatment of atypical teratoid/rhabdoid tumors. Nat. Med. 26, 712–719 (2020).
Donovan, L. K. et al. Locoregional delivery of CAR T cells to the cerebrospinal fluid for treatment of metastatic medulloblastoma and ependymoma. Nat. Med. 26, 720–731 (2020).
Miao, H. et al. EGFRvIII-specific chimeric antigen receptor T cells migrate to and kill tumor deposits infiltrating the brain parenchyma in an invasive xenograft model of glioblastoma. PLoS ONE 9, e94281 (2014).
Saha, D., Martuza, R. L. & Rabkin, S. D. Macrophage polarization contributes to glioblastoma eradication by combination immunovirotherapy and immune checkpoint blockade. Cancer Cell 32, 253–267 (2017).
Ravanpay, A. C. et al. EGFR806-CAR T cells selectively target a tumor-restricted EGFR epitope in glioblastoma. Oncotarget 10, 7080–7095 (2019).
Agliardi, G. et al. Intratumoral IL-12 delivery empowers CAR-T cell immunotherapy in a pre-clinical model of glioblastoma. Nat. Commun. 12, 444 (2021).
Brown, C. E. et al. Regression of glioblastoma after chimeric antigen receptor T-cell therapy. N. Engl. J. Med. 375, 2561–2569 (2016).
Majzner, R. G. et al. GD2-CAR T cell therapy for H3K27M-mutated diffuse midline gliomas. Nature 603, 934–941 (2022).
Vitanza, N. A. et al. Locoregional infusion of HER2-specific CAR T cells in children and young adults with recurrent or refractory CNS tumors: an interim analysis. Nat. Med. 27, 1544–1552 (2021).
Ahmed, N. et al. HER2-specific chimeric antigen receptor-modified virus-specific T cells for progressive glioblastoma: a phase 1 dose-escalation trial. JAMA Oncol. 3, 1094–1101 (2017).
Vitanza, N. A. et al. Intraventricular B7-H3 CAR T cells for diffuse intrinsic pontine glioma: preliminary first-in-human bioactivity and safety. Cancer Discov. 13, 114–131 (2022).
Patterson, J. D., Henson, J. C., Breese, R. O., Bielamowicz, K. J. & Rodriguez, A. CAR T cell therapy for pediatric brain tumors. Front. Oncol. 10, 1582 (2020).
Frigault, M. J. et al. Tisagenlecleucel CAR T-cell therapy in secondary CNS lymphoma. Blood 134, 860–866 (2019).
Frigault, M. J. et al. Safety and efficacy of tisagenlecleucel in primary CNS lymphoma: a phase 1/2 clinical trial. Blood 139, 2306–2315 (2022).
Majzner, R. G. et al. CAR T cells targeting B7-H3, a pan-cancer antigen, demonstrate potent preclinical activity against pediatric solid tumors and brain tumors. Clin. Cancer Res. 25, 2560–2574 (2019).
Gállego Pérez-Larraya, J. et al. Oncolytic DNX-2401 virus for pediatric diffuse intrinsic pontine glioma. N. Engl. J. Med. 386, 2471–2481 (2022).
Cloughesy, T. F. et al. Neoadjuvant anti-PD-1 immunotherapy promotes a survival benefit with intratumoral and systemic immune responses in recurrent glioblastoma. Nat. Med. 25, 477–486 (2019).
Dougan, M., Wang, Y., Rubio-Tapia, A. & Lim, J. K. AGA clinical practice update on diagnosis and management of immune checkpoint inhibitor colitis and hepatitis: expert review. Gastroenterology 160, 1384–1393 (2021).
Lee, D. W. et al. ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells. Biol. Blood Marrow Transplant. 25, 625–638 (2019).
Dutcher, J. P. et al. High dose interleukin-2 (Aldesleukin)—expert consensus on best management practices-2014. J. Immunother. Cancer 2, 26 (2014).
Maus, M. V. et al. Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune effector cell-related adverse events. J. Immunother. Cancer 8, e001511 (2020).
US Department of Health and Human Services. Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0, 155 (US Department of Health and Human Services, 2017).
Siddiqi, T. et al. CD19-directed CAR T-cell therapy for treatment of primary CNS lymphoma. Blood Adv. 5, 4059–4063 (2021).
Brandsma, D., Stalpers, L., Taal, W., Sminia, P. & van den Bent, M. J. Clinical features, mechanisms, and management of pseudoprogression in malignant gliomas. Lancet Oncol. 9, 453–461 (2008).
Okada, H. et al. Immunotherapy response assessment in neuro-oncology: a report of the RANO working group. Lancet Oncol. 16, e534–e542 (2015).
Salvador, A. F., de Lima, K. A. & Kipnis, J. Neuromodulation by the immune system: a focus on cytokines. Nat. Rev. Immunol. 21, 526–541 (2021).
Perrinjaquet, C., Desbaillets, N. & Hottinger, A. F. Neurotoxicity associated with cancer immunotherapy: immune checkpoint inhibitors and chimeric antigen receptor T-cell therapy. Curr. Opin. Neurol. 32, 500–510 (2019).
Posner, J. B., Saper, C. B., Schiff, N. D. & Claassen, J. Plum and Posner’s Diagnosis and Treatment of Stupor and Coma 5th edn (Oxford University Press, 2019).
Sm, A., Pj, T. & Nj, R. Interleukin-1 and neuronal injury. Nat. Rev. Immunol. 5, 629–640 (2005).
Orhan, A., Oliver, U., Carmen, I.-D., Robert, N. & Frauke, Z. Neuronal damage in brain inflammation. Arch. Neurol. 64, 185–189 (2007).
Yirmiya, R. & Goshen, I. Immune modulation of learning, memory, neural plasticity and neurogenesis. Brain Behav. Immun. 25, 181–213 (2011).
Gust, J. & Ishak, G. E. Chimeric antigen receptor T-cell neurotoxicity neuroimaging: more than meets the eye. AJNR Am. J. Neuroradiol. 40, E50–E51 (2019).
Lee, D. W. et al. Current concepts in the diagnosis and management of cytokine release syndrome. Blood 124, 188–195 (2014).
Siegler, E. L. & Kenderian, S. S. Neurotoxicity and cytokine release syndrome after chimeric antigen receptor T cell therapy: insights into mechanisms and novel therapies. Front. Immunol. 11, 1973 (2020).
Strati, P. et al. Clinical efficacy of anakinra to mitigate CAR T-cell therapy-associated toxicity in large B-cell lymphoma. Blood Adv. 4, 3123–3127 (2020).
Brudno, J. N. & Kochenderfer, J. N. Toxicities of chimeric antigen receptor T cells: recognition and management. Blood 127, 3321–3330 (2016).
Brown, B. D. et al. Immune effector cell associated neurotoxicity (ICANS) in pediatric and young adult patients following chimeric antigen receptor (CAR) T-cell therapy: can we optimize early diagnosis? Front. Oncol. 11, 634445 (2021).
Shalabi, H. et al. Systematic evaluation of neurotoxicity in children and young adults undergoing CD22 chimeric antigen receptor T-cell therapy. J. Immunother. 41, 350–358 (2018).
Lee, D. W. & Shah, N. Chimeric Antigen Receptor T-Cell Therapies for Cancer: a Practical Guide 1st edn (Elsevier, 2019).
Acknowledgements
Figure 1 was designed by SciStories LLC. This work was supported by California Institute for Regenerative Medicine CLIN2-12595 (C.L.M., M.M., R.G.M.) and CLIN2-12153 (L.D.W., T.B.D.); National Institutes of Health R01CA263500-01 (C.L.M., M.M., R.G.M.), R01NS092597 (M.M.), DP1NS111132 (M.M.), P50CA165962 (M.M.), R01CA258384 (M.M.), U19CA264504 (M.M.), K08CA201491 (L.D.W), 5K08NS118138-02 (J.G.) and 5U01TR002487-05 (J.P.); the Parker Institute for Cancer Immunotherapy (C.L.M., R.G.M.); CureSearch (C.L.M., M.M., R.G.M.); St Baldrick’s/Stand Up 2 Cancer–Pediatric Cancer Dream Team Translational Research Grant (SU2CAACR-DT1113, C.L.M., M.M.; SU2C-AACR-DT-27-17, N.A.V.); ChadTough Defeat DIPG Foundation (J.M., M.M.); Alex’s Lemonade Stand Foundation (M.M.); Cancer Research UK (M.M.); Virginia and D.K. Ludwig Fund for Cancer Research (M.M., C.L.M.); V Foundation Translational Research Grant (L.D.W); Shurl and Kay Curci Foundation Award, Stanford Maternal & Child Health Research Institute (L.M.P); Cookies for Kid’s Cancer Young Investigator Grant (N.A.V.); DIPG All-In (N.A.V.); Matthew Larson Research Grant (N.A.V.); We Love You Connie Foundation (N.A.V.); Cancer Research UK City of London Centre (K.S., C.R); and Wellcome Trust (C.R.).
Author information
Authors and Affiliations
Corresponding authors
Ethics declarations
Competing interests
C.L.M. holds multiple patents in the arena of CAR T cell therapeutics, is a cofounder and holds equity in Lyell Immunopharma, CARGO Therapeutics and Link Cell Therapies, which are developing CAR-based therapies, and consults for Lyell, CARGO, Link, NeoImmune Tech, Apricity, Nektar, Immatics, Mammoth and Ensoma. R.G.M. holds patents for CAR T cell therapeutics and is a cofounder of and holds equity in CARGO Therapeutics and Link Cell Therapies. R.G.M. has served as a consultant for Lyell Immunopharma, CARGO Therapeutics, Link Cell Therapies, NKarta, Arovella Pharmaceuticals, ImmunAI, Aptorum Group, Zai Labs, Innervate Radiopharmaceuticals, GaDeta and GammaDelta Therapeutics. J.G. is a consultant for Johnson & Johnson. J.D. has been a consultant for Amgen and Unum Therapeutics. M.M. holds patents for CAR T cell therapeutics and holds equity in MapLight Therapeutics. M.L. receives research support from Arbor, BMS, Accuray, Biohaven and Urogen; serves as a consultant to VBI, InCephalo Therapeutics, Merck, Pyramid Bio, Insightec, Biohaven, Sanianoia, Hemispherian, Novocure, Noxxon, InCando, Century Therapeutics, CraniUs, MediFlix and XSense; and is a shareholder in Egret Therapeutics.
Peer review
Peer review information
Nature Medicine thanks David Greer and the other, anonymous, reviewer(s) for their contribution to the peer review of this work. Primary Handling Editor Karen O’Leary, in collaboration with the Nature Medicine team.
Additional information
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
About this article
Cite this article
Mahdi, J., Dietrich, J., Straathof, K. et al. Tumor inflammation-associated neurotoxicity. Nat Med 29, 803–810 (2023). https://doi.org/10.1038/s41591-023-02276-w
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41591-023-02276-w
This article is cited by
-
RACGAP1 promotes the progression and poor prognosis of lung adenocarcinoma through its effects on the cell cycle and tumor stemness
BMC Cancer (2024)
-
Immuntherapie gegen Gliome
Der Nervenarzt (2024)
-
Intrathecal bivalent CAR T cells targeting EGFR and IL13Rα2 in recurrent glioblastoma: phase 1 trial interim results
Nature Medicine (2024)
-
Neurotoxicity of Cancer Immunotherapies Including CAR T Cell Therapy
Current Neurology and Neuroscience Reports (2023)